CD16 expression on neutrophils predicts treatment efficacy of capecitabine in colorectal cancer patients

BMC Immunology

Table 2 Relationship between CD16 expression on CD11b⁺myeloid cells after capecitabine therapy and clinicopathologic characteristics

Characteristics	All patients (n = 134)		CD16⁺ after therapy (n = 65, 48.51%)		CD16^low/− after therapy (n = 69, 51.49%)		P value
Characteristics	n	%	n	%	n	%	P value
Age (years)
<65	70	52.24%	36	51.43%	34	48.57%	0.479
≥65	64	47.76%	29	45.31%	35	54.69%
Gender
Male	82	61.19%	42	51.22%	40	48.78%	0.43
Female	52	38.81%	23	44.23%	29	55.77%
Tumor location
Rectum	68	50.75%	32	47.06%	36	52.94%	0.733
Colon	66	49.25%	33	50.00%	33	50.00%
Tumor Size
≥5 cm	57	42.54%	25	43.86%	32	56.14%	0.354
<5 cm	77	57.46%	40	51.95%	37	48.05%
CEA level after therapy
≤5 ng/ml	114	85.07%	60	52.63%	54	47.37%	0.023
>5 ng/ml	20	14.93%	5	25.00%	15	75.00%
CA199 level after therapy
≤27 ng/ml	116	86.57%	61	52.59%	55	47.41%	0.016
>27 ng/ml	18	13.43%	4	22.22%	14	77.78%
TNM stage (AJCC)
Stage II	98	73.13%	45	45.92%	53	54.08%	0.322
Stage III	36	26.87%	20	55.56%	16	44.44%
Location of recurrence
Loco-regional	3	13.04%	2	40.00%	1	5.56%	0.042
liver + lung	3	13.04%	2	40.00%	1	5.56%
liver	10	43.48%	1	20.00%	9	50.00%
lung	6	26.09%	0	0.00%	6	33.33%
peritoneum	1	4.35%	0	0.00%	1	5.56%

ISSN: 1471-2172